Tazeen Ahmad
Stock Analyst at B of A Securities
(3.44)
# 1,002
Out of 5,240 analysts
219
Total ratings
50.62%
Success rate
3.13%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $262 → $292 | $243.58 | +19.88% | 13 | Apr 16, 2026 | |
| BCAX Bicara Therapeutics | Initiates: Buy | $35 | $20.99 | +66.75% | 1 | Mar 25, 2026 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $29 | $22.18 | +30.75% | 17 | Mar 25, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $139 → $149 | $93.72 | +58.98% | 11 | Mar 20, 2026 | |
| PTCT PTC Therapeutics | Maintains: Buy | $97 → $93 | $73.46 | +26.60% | 20 | Feb 20, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $529 → $462 | $291.48 | +58.50% | 7 | Jan 30, 2026 | |
| BLTE Belite Bio | Initiates: Buy | $195 | $153.52 | +27.02% | 1 | Jan 26, 2026 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $28 | $41.03 | -31.76% | 10 | Jan 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Buy | $627 → $860 | $719.88 | +19.46% | 1 | Jan 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $72 → $58 | $26.46 | +119.20% | 7 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $6 → $7 | $7.25 | -3.45% | 7 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $112 | $85.59 | +30.86% | 1 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $30 | $32.94 | -8.93% | 5 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $53 | $50.17 | +5.64% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $104 | $98.82 | +5.24% | 6 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $880 → $887 | $802.70 | +10.50% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $16 | $18.84 | -15.07% | 26 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $92.23 | +45.29% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $6.67 | +19.94% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $9.60 | +56.25% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $9.60 | -58.33% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $39.60 | -79.80% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $19.80 | +36.36% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $9.87 | +183.69% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $10.45 | +282.78% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $161.32 | +10.96% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $26.80 | -17.91% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $1.78 | +68.54% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $5.45 | +83.49% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $2.14 | +181.03% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $9.24 | +62.34% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.48 | -42.53% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $4.66 | +28.76% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $30.14 | -50.23% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $346.84 | -82.70% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $2.62 | +510.69% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $140.81 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $19.52 | +1,436.89% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.44 | +268.85% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $23.04 | +108.33% | 6 | Oct 10, 2018 |
Ascendis Pharma
Apr 16, 2026
Maintains: Buy
Price Target: $262 → $292
Current: $243.58
Upside: +19.88%
Bicara Therapeutics
Mar 25, 2026
Initiates: Buy
Price Target: $35
Current: $20.99
Upside: +66.75%
ACADIA Pharmaceuticals
Mar 25, 2026
Upgrades: Buy
Price Target: $29
Current: $22.18
Upside: +30.75%
Rhythm Pharmaceuticals
Mar 20, 2026
Maintains: Buy
Price Target: $139 → $149
Current: $93.72
Upside: +58.98%
PTC Therapeutics
Feb 20, 2026
Maintains: Buy
Price Target: $97 → $93
Current: $73.46
Upside: +26.60%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Buy
Price Target: $529 → $462
Current: $291.48
Upside: +58.50%
Belite Bio
Jan 26, 2026
Initiates: Buy
Price Target: $195
Current: $153.52
Upside: +27.02%
Apellis Pharmaceuticals
Jan 21, 2026
Upgrades: Buy
Price Target: $28
Current: $41.03
Upside: -31.76%
Regeneron Pharmaceuticals
Jan 7, 2026
Upgrades: Buy
Price Target: $627 → $860
Current: $719.88
Upside: +19.46%
Ultragenyx Pharmaceutical
Jan 2, 2026
Maintains: Buy
Price Target: $72 → $58
Current: $26.46
Upside: +119.20%
Dec 9, 2025
Maintains: Underperform
Price Target: $6 → $7
Current: $7.25
Upside: -3.45%
Dec 9, 2025
Maintains: Buy
Price Target: $71 → $112
Current: $85.59
Upside: +30.86%
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $32.94
Upside: -8.93%
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $50.17
Upside: +5.64%
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $98.82
Upside: +5.24%
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $802.70
Upside: +10.50%
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $18.84
Upside: -15.07%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $92.23
Upside: +45.29%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $6.67
Upside: +19.94%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $9.60
Upside: +56.25%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $9.60
Upside: -58.33%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $39.60
Upside: -79.80%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $19.80
Upside: +36.36%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $9.87
Upside: +183.69%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $10.45
Upside: +282.78%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $161.32
Upside: +10.96%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $26.80
Upside: -17.91%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $1.78
Upside: +68.54%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $5.45
Upside: +83.49%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $2.14
Upside: +181.03%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $9.24
Upside: +62.34%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.48
Upside: -42.53%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $4.66
Upside: +28.76%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $30.14
Upside: -50.23%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $346.84
Upside: -82.70%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $2.62
Upside: +510.69%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $140.81
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $19.52
Upside: +1,436.89%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.44
Upside: +268.85%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $23.04
Upside: +108.33%